-+ 0.00%
-+ 0.00%
-+ 0.00%
IMMATICS demonstrated the clinical activity of IMA402 PRAME bispecific therapy and IMA203CD8 PRAME cell therapy in advanced solid tumors through two oral presentations at the 2026 ESMO annual meeting.
Share
Listen to the news
IMMATICS demonstrated the clinical activity of IMA402 PRAME bispecific therapy and IMA203CD8 PRAME cell therapy in advanced solid tumors through two oral presentations at the 2026 ESMO annual meeting.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending